Landmark Study Allows Some Liver Transplant Recipients to Stop Anti-Rejection Drugs

Got story updates? Submit your updates here. ›

A groundbreaking study at the University of Pittsburgh has found that some liver transplant recipients may be able to safely stop taking anti-rejection medications long-term. The study enrolled participants like Barbara Bowser, who was preparing for a liver transplant in 2018 and agreed to take part in the research to help advance medical science.

Why it matters

Liver transplant recipients typically must take immunosuppressant drugs for the rest of their lives to prevent organ rejection, but these medications can have serious side effects. This study represents a potential breakthrough that could dramatically improve quality of life for transplant patients if the findings can be replicated and scaled.

The details

The study, led by researchers at the University of Pittsburgh, enrolled a select group of liver transplant recipients and gradually tapered their anti-rejection medications over time. Participants were closely monitored, and those who showed no signs of organ rejection were eventually able to stop taking the drugs altogether.

• Barbara Bowser enrolled in the study in 2018 while preparing for her liver transplant.
• The study has been ongoing since 2018 and is now yielding promising initial results.

What they’re saying

What’s next

Researchers plan to continue monitoring the study participants and publish more detailed findings in the coming years to determine if this approach can be safely adopted as a new standard of care for liver transplant recipients.